Established in 2020, Absea is a global leader in protein engineering, offering transformative solutions to drive advancements in life sciences. With a cutting-edge platform, the company specializes in producing soluble proteins and monoclonal antibodies for a wide range of applications. Its extensive library of 12'000 soluble proteins, covering 60% of the human proteome, is continuously expanding alongside a growing synthetic proteome portfolio. Supported by state-of-the-art facilities in Berlin, China, and the Bay Area, Absea provides advanced technologies for proteomics and interactomics, enabling breakthroughs in AI-driven protein design, diagnostics, and drug development. Positioned as a trusted partner, Absea delivers pioneering protein solutions to scientists and industry innovators worldwide.
Portfolio
- Soluble proteins/antigens for proteomics and mass spectrometry
- Cross-linking mass spectrometry and proteomics service (XL-MS)
- Antibodies for IHC, WB, IP and more
- Antibody pairs and conjugates
- Isotope-labeled proteins
Cross-linking mass spectrometry
Cross-linking mass spectrometry (XL-MS) enables the discovery of protein interactions, binding interfaces, and structural details in a single experiment. Advanced workflows support analyses from purified complexes to whole cells in native environments without protein engineering or lysis. Applications include mapping interactomes, identifying partners of clinically relevant proteins, and discovering interactions for biomarkers or drug targets. Absea also offers mass spectrometry services to characterize interactors of its protein and antibody products.
Figure 1: XL-MS Service details
Advancing protein engineering with AI-driven design and production
Absea leverages AI to revolutionize protein engineering and discovery, integrating machine learning algorithms to optimize protein design, predict interactions, and accelerate drug development. By analyzing complex proteomic data, AI enhances the efficiency of identifying novel targets and understanding disease mechanisms. This advanced approach supports the development of innovative solutions in diagnostics and therapeutics, ensuring precision and scalability in life sciences research.
